Citadel Advisors
VAXX

Citadel Advisors’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Citadel Advisors’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-79,444
Closed -$67.5K – 15700
2023
Q4 		$67.5K Buy
+79,444
New +$76.7K ﹤0.01% 11431
2022
Q2 		– Sell
-10,766
Closed -$46K – 14437
2022
Q1 		$46K Buy
+10,766
New +$59.5K ﹤0.01% 12854

Other funds holding VAXX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
SAS
Stelac Advisory Services New York $494M AUM 23.25% 1-Year Est. Return

Citadel Advisors's VAXX Position: Q1 2024 in Review

Citadel Advisors sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q1 2024, closing a stake of 79,444 shares — an estimated $67.5K sold.

Citadel Advisors first reported a position in VAXX in Q1 2022 and held it in 2 quarters. The position peaked at $67.5K in Q4 2023. 58 funds tracked by Wall St. Rank hold VAXX as of Q1 2024.

  • Citadel Advisors reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 79,444 Vaxxinity, Inc. Class A Common Stock shares in Q1 2024, an estimated $67.5K.
  • Citadel Advisors first reported a position in Vaxxinity, Inc. Class A Common Stock in Q1 2022 and held it in 2 quarters.
  • Citadel Advisors's Vaxxinity, Inc. Class A Common Stock position peaked at $67.5K in Q4 2023.
  • 58 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.